SCHEMBL707231

SCHEMBL707231

CS(=O)(=O)OC1CCOC1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.31
GPR119 Q8TDV5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709288 1.00 LRRK2 (0.31) LRRK2GPR119
SCHEMBL707230 1.00 LRRK2 (0.31) LRRK2GPR119
SCHEMBL3826761 0.91 GPR119 (0.31) GPR119
SCHEMBL28756731 0.88 CA1 (0.33)
SCHEMBL707215 0.88 CA1 (0.33)
SCHEMBL224278 0.86 CA1 (0.33)
SCHEMBL9562903 0.81
SCHEMBL28718773 0.81
SCHEMBL28363128 0.79 PDE4D (0.33)
SCHEMBL26699713 0.79 CA1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 438 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138986-A1 PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES BLUEPRINT MEDICINES CORP (US) 2026-05-21 US disclosed
US-20260132139-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-14 US disclosed
EP-4430042-B1 6-HETERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS INC (US) 2026-02-18 EP disclosed
US-12552786-B2 Inhibitors of αvβ6 integrin MORPHIC THERAPEUTIC, INC. (US) 2026-02-17 US disclosed
EP-4692076-A1 HIV INHIBITOR COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 EP disclosed
US-12514859-B2 Pyrazole pyrimidine derivative and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2026-01-06 US disclosed
US-12479853-B2 HIV inhibitor compounds GILEAD SCIENCES, INC. (US) 2025-11-25 US disclosed
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING REMIX THERAPEUTICS INC (US) 2025-10-30 US disclosed
EP-3909949-B1 ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS GILEAD SCIENCES INC (US) 2025-10-15 EP disclosed
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION 2025-07-10 US disclosed
US-6498160-B2 FOR THERAPY OF EMPHYSEMA, CHRONIC BRONCHITIS, ASTHMA AND ALLERGIC RHINITIS ZAMBON GROUP S.P.A. (IT) 2002-12-24 US disclosed
EP-1244645-A1 STEREOSPECIFIC HYDROLYSIS OF OPTICALLY ACTIVE ESTERS Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2002-10-02 EP disclosed
US-20020058662-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors ZAMBON GROUP S.P.A. (IT) 2002-05-16 US disclosed
US-6340684-B1 TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, ALLERGIC RHINITIS ZAMBON GROUP S.P.A. (IT) 2002-01-22 US disclosed
WO-2001047908-A1 STEREOSPECIFIC HYDROLYSIS OF OPTICALLY ACTIVE ESTERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2001-07-05 WO disclosed
US-5489606-A FUNGICIDES, HUMAN, VETERNARY MEDICINE SANKYO COMPANY, LIMITED (JP) 1996-02-06 US disclosed
US-5393769-A Thio-, sulfinyl- or sulfonyl-substituted SANKYO COMPANY, LIMITED (JP) 1995-02-28 US disclosed
CN-1026786-C Anti-fungal triazole derivatives, their preparation and uses SANKYO CO (JP) 1994-11-30 CN disclosed
CN-1059336-A Anti-fungal triazole derivatives and preparation thereof and purposes SANKYO CO (JP) 1992-03-11 CN disclosed
EP-0473387-A2 Anti-fungal triazole derivatives, their preparation and uses Sankyo Company Limited (JP) 1992-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058662-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 LRRK2 3011/4885GPR119 755/4885
US-20250332173-A1 COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING SNRPA, NSUN2, SNRPA1 LRRK2 3766/4885GPR119 4169/4885
US-12552786-B2 Inhibitors of αvβ6 integrin ITGB6, ITGB1, ITGA6 LRRK2 1696/4885GPR119 1650/4885
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS ERBB2, MERTK, ABL1 LRRK2 1267/4885GPR119 670/4885
US-12479853-B2 HIV inhibitor compounds NFATC1, SAMHD1, CCR5 LRRK2 1100/4885GPR119 2624/4885
US-20260132139-A1 HIV INHIBITOR COMPOUNDS SLC11A2, SLC6A15, NHERF1 LRRK2 903/4885GPR119 3532/4885
US-20260138986-A1 PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES KIT, PDGFRA, PDGFRB LRRK2 278/4885GPR119 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.